Alemtuzumab remains in the news

A

Sanofi pulls Campath to clear way for higher-priced Lemtrada
FiercePharma
Genzyme has been developing Campath-slash-Lemtrada for MS, hoping to become a big player in that disease area. But MS drugs such as Biogen Idec’s ($BIIB) Tysabri and Novartis’ ($NVS) Gilenya have price tags much higher than Campath’s, at least at …
See all stories on this topic »

Sanofi withdraws Campath in US and EU
Pharma Times
French drugmaker Sanofi’s Genzyme unit is pulling its cancer drug Campath/MabCampath from markets on both sides of the Atlantic in order to optimise the pending launch of the drug as a treatment for multiple sclerosis, according to reports. The company …
See all stories on this topic »

Genzyme Avoids Marketing Misstep by Pulling Drug Used – FDA News
Apparently assured of U.S. and EU approval for Lemtrada in relapsing multiple sclerosis (MS), Genzyme is pulling its leukemia drug Campath, which has the …
fdanews.com/newsletter/article?articleId=148844&issueId…


CoI: multiple

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

2 comments

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives